Defective Drugs

Zantac Litigation Update

The popular heartburn medication Zantac (ranitidine) was recalled and taken off shelves in September of 2019 after the Food and Drug Administration announced that it had found the cancer-causing chemical N-nitrosodimethylamine (NDMA) in samples of Zantac. On February 6, 2020 the Judicial Panel for Multidistrict Litigation formed MDL No. 2924 in the federal court in… read more

Zantac Recall-FDA Update

New FDA Announcement Calls for Zantac to be Pulled from Market The popular heartburn medication Zantac (ranitidine) was recalled and taken off shelves in September of 2019 after the Food and Drug Administration announced that it had found the cancer-causing chemical N-nitrosodimethylamine (NDMA) in samples of Zantac. The FDA has recently taken further action, announcing… read more

Dozens of Zantac carcinogen lawsuits consolidated in one court

When officials revealed the possible existence of a dangerous carcinogen in Zantac, many longtime users of the heartburn drug took action. Lawsuits popped up across the country, all stemming from the worrying discovery of NDMA in the drug. Now, more than 140 of these federal lawsuits will be moving forward in a single court. Centralizing… read more

Zantac Lawsuit: What You Should Know

As of September of 2019, the popular heartburn medicine Zantac (ranitidine) has been recalled and taken off shelves in pharmacies after the Food and Drug Administration announced that it had found the cancer-causing chemical N-nitrosodimethylamine (NDMA) in some batches of Zantac. Major pharmaceutical companies such as Sanofi-Aventis, Chattem, Inc., Boehringer Ingelheim, Pfizer, and GlaxoSmithKline have… read more

Zantac Linked to Cancer

As of September of 2019, the popular heartburn medicine Zantac (ranitidine) has been recalled and taken off shelves in pharmacies after the Food and Drug Administration announced that it had found the cancer-causing chemical N-nitrosodimethylamine (NDMA) in some batches of Zantac. Major pharmaceutical companies such as Sanofi-Aventis, Chattem, Inc., Boehringer Ingelheim, Pfizer, and GlaxoSmithKline have… read more

Ranitidine (Zantac) recalled due to cancer risk

Zantac is one of the most popular heartburn medications in the United States. Millions of people use it frequently. That’s all due to change, as recent tests have revealed a cancer risk and major drugstores have started pulling the products. Here is what you need to know. Findings in September This is all very new,… read more

Zantac Recall

The U.S. Food and Drug Administration (FDA) publicly announced in September 2019 that dangerously high levels of the carcinogenic substance N-Nitrosodimethylamine (NDMA) have been found in the popular over-the-counter heartburn medication, Zantac. This means that millions of people who have been taking Zantac have regularly been ingesting a chemical that is notorious for causing cancer…. read more

Bayer says it will no longer sell Essure birth control implants

Following the continuous efforts by health advocates and thousands of women, Bayer announced that it will no longer sell its Essure birth control implant by the end of the year. The permanent birth control method resembles the spring of a ballpoint pen and does not require an incision or invasive surgery. The company says the… read more

Xarelto-Defective Drugs Lawsuits

Thousands of lawsuits are now being filed against the manufacturers of the blood thinner, Xarelto. These claims include that patients of Xarelto, have suffered serious injuries and even death as a product of taking the anti-coagulant drug. Specifically, they allege that the side effects of Xarelto include excessive and most importantly, uncontrollable bleeding which they… read more

Xarelto-Defective Drugs

The defective drug, Xarelto, a blood thinner and anticoagulant drug manufactured to treat and prevent blood clots is now the source of thousands of lawsuits commenced against the drug’s developers, Johnson & Johnson and Bayer.  The US Food and Drug Administration approved Xarelto as a treatment for deep vein thrombosis, atrial fibrillation, and pulmonary embolism as well… read more